RLN2 and neoplasm: To further investigate whether the enhanced antitumor efficacy observed with RLN2-secreting CAR-T cells in the SU86.86 subcutaneous tumor model was dependent on the specific target antigen, we evaluated an alternative CAR construct targeting claudin-4, an adhesion molecule highly expressed on SU86.86 cells.